|
|
|
| Data analysis of implementating national centralized drug procurement reform in a tertiary hospital in Beijing |
| ZHANG Xu XU Xinyue TANG Jiaji ZHANG Tongyan |
| Medical Insurance Office, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China |
|
|
|
Abstract Objective To analyze the impact on outpatient expenses and medical insurance fund payment of Beijing Tongren Hospital, Capital Medical University (hereinafter referred to as “our hospital”) after implementing the pilot program of centralized drug procurement and use organized by the state, so as to provide data support for policy promotion. Methods The information of patients who used the national drugs to purchase drugs intensively and the drugs with the same generic name but not winning the bid from April to June in both 2018 and 2019 were collected. The data of the average cost before and after department reform was used. The changes of average cost before and after the reform and the use of medical insurance fund were compared and analyzed. Results After the implementation of the national centralized drug procurement and use pilot work, the increase of outpatient and sub average drug costs slowed down, and the proportion of outpatient and emergency drugs decreased from 33.21% to 32.42%. Among the drugs purchased by the state, the number of drugs used in outpatient service ranked the top 10, and the second average cost was significantly lower than that before the reform, with a maximum decrease of 72.41%, saving 2 183 600 yuan of medical insurance fund. Conclusion The pilot program implementation of the national centralized drug procurement plays an important role in controlling the unreasonable growing of outpatient drug costs, can effectively reduce the burden of patients, improve the efficiency of using medical insurance funds.
|
|
|
|
|
|
[1] 国务院办公厅.关于完善公立医院药品集中采购工作的指导意见（国办发[2015]7号）[Z].2015.
[2] 孟丽君.沈阳市药品集中采购使用试点运行分析[J].中国医疗保险，2019，8（8）：28-31.
[3] 朱佳英，任晋文，华恃彬.“4+7”城市药品带量采购在公立医院的实施效果预测与探讨[J].浙江医学，2019，41（10）：1103-1107.
[4] 杨丽娟，张宇晴，张丽芳，等.药品合理定价影响因素研究[J].中国医院，2018，22（10）：23-25.
[5] 荣雪菁，孙强.我国相关省份原研药及仿制药价格比较[J].中国卫生经济，2018，37（11）：33-36.
[6] 李琛，刘艺敏，王文杰，等.我国药品集中采购工作回顾与展望[J].中国医院管理，2018，38（9）：17-23.
[7] 新华网.减轻药品负担—国家医保局有关负责人就国家组织药品集中采购和使用试点方案答记者问[EB/OL].http：www.nhsa.gov.cn/art/2019/1/18/art_14_845.html.
[8] 郑树忠，龚波，朱诗翀，等.医改背景下上海药品集中采购推行“两票制"的地方实践及思考[J].中国卫生资源，2017，20（5）：365-367.
[9] 袁姣，左克源，周健丘，等.公立医院基本药品集中采购政策实施效果评价[J].中国医院药学杂志，2017，37（9）：783-786.
[10] 王妍，武志昂.《国家组织药品集中采购和使用试点工作监测方案》要点分析[J].中国药房，2019，30（17）：2317-2321.
[11] 宋璧麟，袁姣，叶霖.2000年-2018年6月国内药品集中采购研究的可视化分析[J].中国药房，2019，30（2）：160-164.
[12] 张欣，傅鸿鹏.对完善我国公立医院药品采购机制的建议[J].中国医院管理，2015，35（2）：13-15.
[13] 尤晓敏，吕旭峰，杨悦.我国公立医院药品带量采购制度实施状况研究[J].中国药房，2017，28（31）：4345-4349.
[14] 陈昊，饶苑弘.新时代的药品带量采购实践与思考[J].中国药物经济学，2019，14（7）：19-26.
[15] 崔啸天，傅鸿鹏，刘昉.新一轮药品集中采购价格10省份间对比研究[J].中国医院管理，2018，38（1）：62-66.
[16] 王焱琪，郭朗，孙利华.对“4+7”药品用量落实问题的探讨[J].中国医疗保险，2019，8（8）：40-44.
[17] 蔡雪妮.中国药品集中采购的演变以及与医保支付的逻辑关系[J].中国卫生政策研究，2017，10（6）：6-12.
[18] 常峰，刘洪强，罗修英.欧盟国家药品招标采购制度介绍及其对我国的启示[J].中国医药工业杂志，2015，46（11）：1254-1258.
[19] 胡善联.带量采购的经济学理论基础和影响分析[J].卫生软科学，2019，33（1）：3-5.
[20] 舒茜，姚峥嵘，王艳翚，等.药品带量采购政策的利益相关者分析[J].卫生经济研究，2019，36（8）：8-12.
[21] 周萍，赵翔，艾丹丹，等.新时期药品带量采购机制研究[J].中国卫生经济，2019，38（5）：78-80. |
|
|
|
